Market cap
$380 Mln
Revenue (TTM)
$22 Mln
P/E Ratio
--
P/B Ratio
4.7
Div. Yield
0 %
Key Ratios and Highlights
| Growth Score (%) | Quarterly | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | QoQ | YoY | 1-Year | 3-Years | 5-Years |
| Revenue | -13.84 | 9.09 | 35.21 | 79.33 | 73.55 |
| EBIT | 4.24 | 15.16 | 22.66 | 11.43 | 9.29 |
| Net Profit | -186.98 | 25.75 | 139.00 | 34.38 | 17.97 |
| EPS | -137.85 | 58.34 | 150.64 | 34.41 | -- |
| Book Value | -- | -- | -53.44 | -36.86 | -- |
| Key Ratios (%) | Average | Annual (TTM) | |||
|---|---|---|---|---|---|
| Particulars | 3-Years | 5-Years | TTM | Dec-22 | Dec-21 |
| EBIT-Margin
| -4,680.27 | -6,448.26 | -467.13 | -452.22 | -7,539.34 |
| Net Margin
| -- | -- | 319.87 | -- | -- |
| Return on equity
| -29.16 | -51.38 | 76.80 | -5.12 | -18.72 |
| Return on Capital
| -23.44 | -47.20 | -- | -3.70 | -14.37 |
| Return on Assets
| -19.88 | -40.37 | 26.07 | -2.91 | -12.05 |
| Debt to Equity (x)
| -- | -- | 0.20 | 0.59 | 0.28 |
Profitability
ROCE
--
--
Earning before interest and taxes / (Average net worth + Average total Debt) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
-3.70
|
-14.37
|
-52.25
|
-49.79
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
ROE
76.80
Higher than Peers by 57.83
Profit after tax / Average Net worth * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
76.80
|
-5.12
|
-18.72
|
-63.64
|
-53.53
|
|
Peer Median
|
18.97
|
--
|
--
|
--
|
--
|
ROA
26.07
Higher than Peers by 23.21
Profit after tax / Average Total assets * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
26.07
|
-2.91
|
-12.05
|
-44.69
|
-42.71
|
|
Peer Median
|
2.86
|
--
|
--
|
--
|
--
|
EBIT Margin
-467.13
Lower than Peers by 482.95
Operating profit (EBIT) / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
-467.13
|
-452.22
|
-7,539.34
|
-6,049.25
|
-6,879.15
|
|
Peer Median
|
15.82
|
--
|
--
|
--
|
--
|
Net Margin
319.87
Higher than Peers by 311.64
Net profit / Total Income (Net sales plus other income) * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
319.87
|
-112.84
|
-7,525.67
|
-5,856.61
|
-6,503.06
|
|
Peer Median
|
8.23
|
--
|
--
|
--
|
--
|
Cash Profit Margin
0.00
--
(Net profit + Depreciation) / Gross Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
0.00
|
--
|
--
|
--
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Revenue Growth
35.21
Higher than Peers by 27.16
Year on year growth in net sales
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
35.21
|
13.46
|
-0.81
|
0.03
|
0.21
|
|
Peer Median
|
8.05
|
--
|
--
|
--
|
--
|
EBIT Growth
22.66
Higher than Peers by 14.40
Year on year growth in operating profit (EBIT)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
22.66
|
13.24
|
76.80
|
9.19
|
26.45
|
|
Peer Median
|
8.26
|
--
|
--
|
--
|
--
|
Net Profit Growth
139.00
Higher than Peers by 131.27
Year on year growth in profit after tax
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
139.00
|
78.31
|
76.08
|
7.00
|
29.10
|
|
Peer Median
|
7.73
|
--
|
--
|
--
|
--
|
EPS Growth
150.64
Higher than Peers by 140.25
Year on year growth in earnings per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
150.64
|
0.78
|
0.82
|
0.07
|
0.38
|
|
Peer Median
|
10.39
|
--
|
--
|
--
|
--
|
Book Value Growth
-63.60
Lower than Peers by 68.48
Year on year growth in book value per share
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
-63.60
|
--
|
--
|
--
|
--
|
|
Peer Median
|
4.87
|
--
|
--
|
--
|
--
|
Solvency
Debt to Equity
0.20
Lower than Peers by 0.39
Total debt / Net worth
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
0.20
|
0.59
|
0.28
|
0.33
|
0.15
|
|
Peer Median
|
0.59
|
--
|
--
|
--
|
--
|
Short term debt to equity ratio
0.19
--
(Short term borrowings / Net worth)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
0.19
|
0.16
|
0.04
|
0.08
|
0.02
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Current Ratio
3.12
Higher than Peers by 1.47
Current Assets / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
3.12
|
2.78
|
6.43
|
4.34
|
6.26
|
|
Peer Median
|
1.65
|
--
|
--
|
--
|
--
|
Quick Ratio
2.98
Higher than Peers by 1.78
(Current Assets - Inventory) / Current Liabilities and Provisions
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
2.98
|
2.72
|
6.39
|
4.32
|
--
|
|
Peer Median
|
1.20
|
--
|
--
|
--
|
--
|
Interest Coverage
18.41
Higher than Peers by 13.64
Earning before interest and taxes (EBIT) / Interest Expenses
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
18.41
|
-33.86
|
-53.32
|
-67.43
|
-112.40
|
|
Peer Median
|
4.77
|
--
|
--
|
--
|
--
|
Operating Efficiency
Debtors to sales
66.03
Higher than Peers by 44.76
Debtors outstanding / Net Sales * 100
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
66.03
|
206.26
|
6,667.29
|
702.20
|
651.65
|
|
Peer Median
|
21.27
|
--
|
--
|
--
|
--
|
Asset Turnover
0.08
Lower than Peers by 0.32
Sales / Average Total Assets
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
0.08
|
0.03
|
0.00
|
0.01
|
0.01
|
|
Peer Median
|
0.40
|
--
|
--
|
--
|
--
|
Receivable days
--
--
Average Debtors / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
1,218.51
|
19,065.97
|
2,434.86
|
2,115.78
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Inventory Days
--
--
Average Inventory / Sales * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
406.53
|
2,166.45
|
283.42
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Payable days
--
--
Average Creditors / Cost of goods sold * 365
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
1,450.64
|
15,216.86
|
4,433.93
|
6,830.63
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Cash Conversion Cycle
--
--
Receivable Days + Inventory Days - Payable Days
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
174.40
|
6,015.56
|
-1,715.65
|
--
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Valuation
Price / Earnings
--
--
Current share price divided by earning per share in the last twelve months
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
-0.60
|
-0.46
|
-0.28
|
-0.83
|
|
Peer Median
|
37.32
|
--
|
--
|
--
|
--
|
Price / Book Value
4.74
Lower than Peers by 3.02
Current share price divided by book value per share in the latest financial year
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
4.74
|
0.05
|
0.08
|
0.24
|
0.45
|
|
Peer Median
|
7.75
|
--
|
--
|
--
|
--
|
Dividend Yield
--
--
Dividend per share in the past twelve months divided by current share price
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
--
|
--
|
--
|
--
|
--
|
|
Peer Median
|
0.50
|
--
|
--
|
--
|
--
|
EV/EBITDA
-4.54
--
Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
-4.54
|
10.01
|
4.05
|
0.62
|
0.88
|
|
Peer Median
|
--
|
--
|
--
|
--
|
--
|
Market Cap
380
Lower than Peers by 2,141
Current Share price multiplied by latest total number of shares outstanding
|
Company Name
|
TTM
|
Dec-22
|
Dec-21
|
Dec-20
|
Dec-19
|
|---|---|---|---|---|---|
|
Orchard Therapeutics - ADR
|
380
|
--
|
--
|
--
|
--
|
|
Peer Median
|
2,521
|
--
|
--
|
--
|
--
|